

Richard S E Keefe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2477981/publications.pdf>

Version: 2024-02-01

279
papers

34,381
citations

5574

82
h-index

3732

179
g-index

291
all docs

291
docs citations

291
times ranked

19085
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 113, 110464.	4.8	3
2	Basic auditory processing and emotion recognition in individuals at clinical high risk for psychosis. <i>Schizophrenia Research: Cognition</i> , 2022, 27, 100225.	1.3	0
3	Digital Intervention for Cognitive Deficits in Major Depression: A Randomized Controlled Trial to Assess Efficacy and Safety in Adults. <i>American Journal of Psychiatry</i> , 2022, 179, 482-489.	7.2	17
4	Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders. <i>Neuropsychopharmacology</i> , 2021, 46, 844-850.	5.4	6
5	Can IQ moderate the response to cognitive remediation in people with schizophrenia?. <i>Journal of Psychiatric Research</i> , 2021, 133, 38-45.	3.1	12
6	Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. <i>Lancet Psychiatry</i> , 2021, 8, 191-201.	7.4	58
7	Cognitive Subtyping in Schizophrenia: A Latent Profile Analysis. <i>Schizophrenia Bulletin</i> , 2021, 47, 712-721.	4.3	17
8	Exploring the role of age as a moderator of cognitive remediation for people with schizophrenia. <i>Schizophrenia Research</i> , 2021, 228, 29-35.	2.0	11
9	Where do we cut the bell-shaped curve of CIAS?. <i>Schizophrenia Research</i> , 2021, 228, 633-634.	2.0	1
10	Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders. <i>Neuropsychopharmacology</i> , 2021, 46, 1802-1810.	5.4	17
11	Virtual Reality Functional Capacity Assessment Tool (VRFCAT-SL) in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1917-1925.	2.8	4
12	Deficits in generalized cognitive ability, visual sensorimotor function, and inhibitory control represent discrete domains of neurobehavioral deficit in psychotic disorders. <i>Schizophrenia Research</i> , 2021, 236, 54-60.	2.0	2
13	A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale. <i>Microbial Biotechnology</i> , 2021, 15, 1315-1325.	1.7	7
14	Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning. <i>Microbial Biotechnology</i> , 2020, 14, 106-114.	1.7	17
15	The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures. <i>Schizophrenia Research: Cognition</i> , 2020, 19, 100161.	1.3	2
16	Theta Burst for Cognitive Remediation in Schizophrenia. <i>Journal of ECT</i> , 2020, 36, 72-74.	0.6	1
17	M120. IMPAIRED CLINICAL INSIGHT AS A PREDICTOR OF RELAPSE IN SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020, 46, S180-S181.	4.3	0
18	Factor structure of cognitive performance and functional capacity in schizophrenia: Evidence for differences across functional capacity measures. <i>Schizophrenia Research</i> , 2020, 223, 297-304.	2.0	9

#	ARTICLE	IF	CITATIONS
19	Assessing instrumental activities of daily living (iADL) with a game-based assessment for individuals with schizophrenia. <i>Schizophrenia Research</i> , 2020, 223, 166-172.	2.0	6
20	Requisite Skills and the Meaningful Measurement of Cognition. <i>JAMA Psychiatry</i> , 2020, 77, 1103.	11.0	0
21	A randomized proof-of-mechanism trial applying the "fast-fail" approach to evaluating μ -opioid antagonism as a treatment for anhedonia. <i>Nature Medicine</i> , 2020, 26, 760-768.	30.7	129
22	A new measure of authentic auditory emotion recognition: Application to patients with schizophrenia. <i>Schizophrenia Research</i> , 2020, 222, 450-454.	2.0	4
23	A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. <i>The Lancet Digital Health</i> , 2020, 2, e168-e178.	12.3	186
24	Verbal memory measurement towards digital perspectives in first-episode psychosis: A review. <i>Schizophrenia Research: Cognition</i> , 2020, 21, 100177.	1.3	6
25	Corticolimbic brain anomalies are associated with cognitive subtypes in psychosis: A longitudinal study. <i>European Psychiatry</i> , 2020, 63, e40.	0.2	3
26	Approaches to attenuated psychosis syndrome treatments: A perspective on the regulatory issues. <i>Schizophrenia Research: Cognition</i> , 2019, 18, 100155.	1.3	3
27	T32. INTACT AUDITORY PERCEPTION IN INDIVIDUALS AT CLINICAL HIGH RISK FOR PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2019, 45, S215-S215.	4.3	2
28	O5.7. VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT IN PATIENTS WITH SCHIZOPHRENIA: CORRELATES OF PERFORMANCE OF SOLITARY AND SOCIALLY RELEVANT TASKS. <i>Schizophrenia Bulletin</i> , 2019, 45, S175-S175.	4.3	1
29	Virtual reality assessment of functional capacity in people with Schizophrenia: Associations with reduced emotional experience and prediction of functional outcomes. <i>Psychiatry Research</i> , 2019, 277, 58-63.	3.3	10
30	Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS). <i>Schizophrenia Research</i> , 2019, 210, 30-38.	2.0	7
31	Why are there no approved treatments for cognitive impairment in schizophrenia?. <i>World Psychiatry</i> , 2019, 18, 167-168.	10.4	21
32	Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial. <i>Schizophrenia Research</i> , 2019, 208, 182-189.	2.0	22
33	The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 82-84.	46.4	52
34	Basic auditory processing deficits and their association with auditory emotion recognition in schizophrenia. <i>Schizophrenia Research</i> , 2019, 204, 155-161.	2.0	19
35	Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. <i>Schizophrenia Bulletin</i> , 2019, 45, 350-359.	4.3	28
36	Large-Scale Network Topology Reveals Heterogeneity in Individuals With at Risk Mental State for Psychosis: Findings From the Longitudinal Youth-at-Risk Study. <i>Cerebral Cortex</i> , 2018, 28, 4234-4243.	2.9	16

#	ARTICLE	IF	CITATIONS
37	Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls. <i>Translational Psychiatry</i> , 2018, 8, 78.	4.8	49
38	A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 442-447.	2.1	1
39	Polygenic signal for symptom dimensions and cognitive performance in patients with chronic schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2018, 12, 11-19.	1.3	21
40	Latent Profile Analysis and Conversion to Psychosis: Characterizing Subgroups to Enhance Risk Prediction. <i>Schizophrenia Bulletin</i> , 2018, 44, 286-296.	4.3	28
41	Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia. <i>Schizophrenia Research</i> , 2018, 193, 83-90.	2.0	13
42	Genetic correlates of insight in schizophrenia. <i>Schizophrenia Research</i> , 2018, 195, 290-297.	2.0	16
43	T206. DOES AGE INFLUENCE RESPONSE TO COGNITIVE REMEDIATION?. <i>Schizophrenia Bulletin</i> , 2018, 44, S196-S197.	4.3	0
44	P1â€050: ADJUDICATING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE AS A NOVEL ENDPOINT EVENT IN THE TOMMORROW STUDY: A DELAYâ€OFâ€ONSET PHASE 3 CLINICAL TRIAL. <i>Alzheimer's and Dementia</i> , 0.8 2018, 14, P286.		0
45	Take This Cognitive Training Efficacy Bar Fight Outside (to a Regulatory Agency). <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 900-902.	1.5	0
46	Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	2.2	24
47	Factor structure of the positive and negative syndrome scale (PANSS) in people at ultra high risk (UHR) for psychosis. <i>Schizophrenia Research</i> , 2018, 201, 85-90.	2.0	11
48	Longitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis. <i>JAMA Psychiatry</i> , 2018, 75, 929.	11.0	54
49	T111. PANSS NEGATIVE SYMPTOM DIMENSIONS ACROSS GEOGRAPHICAL REGIONS: IMPLICATIONS FOR SOCIAL, LINGUISTIC AND CULTURAL CONSISTENCY. <i>Schizophrenia Bulletin</i> , 2018, 44, S159-S159.	4.3	0
50	TOMMORROW neuropsychological battery: German language validation and normative study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 314-323.	3.7	9
51	The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project. <i>Schizophrenia Research</i> , 2018, 195, 306-317.	2.0	17
52	Impaired Context Processing is Attributable to Global Neuropsychological Impairment in Schizophrenia and Psychotic Bipolar Disorder. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw081.	4.3	26
53	Validation of the tablet-administered Brief Assessment of Cognition (BAC App). <i>Schizophrenia Research</i> , 2017, 181, 100-106.	2.0	62
54	Validation of the Persian version of the Schizophrenia Cognition Rating Scale (SCoRS) in patients with schizophrenia. <i>Asian Journal of Psychiatry</i> , 2017, 27, 12-15.	2.0	8

#	ARTICLE	IF	CITATIONS
55	Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. <i>Schizophrenia Research</i> , 2017, 190, 172-179.	2.0	33
56	Placebo Response and Practice Effects in Schizophrenia Cognition Trials. <i>JAMA Psychiatry</i> , 2017, 74, 807.	11.0	34
57	Cognitive Decline and Disrupted Cognitive Trajectory in Schizophrenia. <i>JAMA Psychiatry</i> , 2017, 74, 535.	11.0	19
58	Cognitive burden of anticholinergic medications in psychotic disorders. <i>Schizophrenia Research</i> , 2017, 190, 129-135.	2.0	71
59	The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 651-656.	1.4	37
60	868. Early Intervention in Attenuated Psychosis Syndrome: A Phase II Study Evaluating Efficacy, Safety, and Tolerability of Oral BI 409306. <i>Biological Psychiatry</i> , 2017, 81, S351.	1.3	2
61	The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth With Attenuated Psychotic Symptoms. <i>Schizophrenia Bulletin</i> , 2017, 43, 57-63.	4.3	84
62	[P4â€“578]: EXPANDING THE BRIEF ASSESSMENT OF COGNITION (BACâ€“APP) FOR ASSESSMENT OF COGNITION IN AGING: INITIAL FINDINGS FROM AN ONGOING NORMATIVE STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1574.	0.8	1
63	M25. Development and Validation of the Brief Assessment of Validation in Schizophrenia (BAC-App). <i>Schizophrenia Bulletin</i> , 2017, 43, S220-S220.	4.3	2
64	Using the Positive and Negative Syndrome Scale (PANSS) to Define Different Domains of Negative Symptoms: Prediction of Everyday Functioning by Impairments in Emotional Expression and Emotional Experience. <i>Innovations in Clinical Neuroscience</i> , 2017, 14, 18-22.	0.1	39
65	Negative Symptom Dimensions of the Positive and Negative Syndrome Scale Across Geographical Regions: Implications for Social, Linguistic, and Cultural Consistency. <i>Innovations in Clinical Neuroscience</i> , 2017, 14, 30-40.	0.1	61
66	Predicting Schizophrenia. <i>JAMA Psychiatry</i> , 2016, 73, 441.	11.0	0
67	Validation of a Computerized test of Functional Capacity. <i>Schizophrenia Research</i> , 2016, 175, 90-96.	2.0	53
68	Disrupted latent inhibition in individuals at ultra high-risk for developing psychosis. <i>Schizophrenia Research: Cognition</i> , 2016, 6, 1-8.	1.3	12
69	Treating cognitive impairment in depression: an unmet need. <i>Lancet Psychiatry</i> , the, 2016, 3, 392-393.	7.4	8
70	Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2016, 42, 335-343.	4.3	78
71	A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processingâ€“Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 799-806.	2.2	22
72	Dr Kantrowitz and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1353-e1353.	2.2	0

#	ARTICLE	IF	CITATIONS
73	An abbreviated version of the brief assessment of cognition in schizophrenia (BACS). <i>European Journal of Psychiatry</i> , 2015, 29, 131-134.	1.3	3
74	Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 374-381.	1.4	81
75	Working memory impairment in probands with schizoaffective disorder and first degree relatives of schizophrenia probands extend beyond deficits predicted by generalized neuropsychological impairment. <i>Schizophrenia Research</i> , 2015, 166, 310-315.	2.0	23
76	Understanding Symbol Coding in Schizophrenia. <i>Biological Psychiatry</i> , 2015, 78, 744-746.	1.3	5
77	Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2015, 42, sbv111.	4.3	34
78	A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2015, 40, 2025-2037.	5.4	258
79	Observable Social Cognition "A Rating Scale: an interview-based assessment for schizophrenia. <i>Cognitive Neuropsychiatry</i> , 2015, 20, 198-221.	1.3	40
80	Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an $\alpha 7$ Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia. <i>Neuropsychopharmacology</i> , 2015, 40, 3053-3060.	5.4	120
81	Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis " Findings from the Longitudinal Youth at Risk Study (LYRIKS). <i>Schizophrenia Research</i> , 2015, 164, 8-14.	2.0	94
82	A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. <i>Schizophrenia Research</i> , 2015, 164, 136-142.	2.0	59
83	Reduced white matter integrity and verbal fluency impairment in young adults with bipolar disorder: A diffusion tensor imaging study. <i>Journal of Psychiatric Research</i> , 2015, 62, 115-122.	3.1	47
84	Lack of Evidence for Regional Brain Volume or Cortical Thickness Abnormalities in Youths at Clinical High Risk for Psychosis: Findings From the Longitudinal Youth at Risk Study: Table 1.. <i>Schizophrenia Bulletin</i> , 2015, 41, 1285-1293.	4.3	51
85	Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale. <i>European Neuropsychopharmacology</i> , 2015, 25, 176-184.	0.7	44
86	Methods for Delivering and Evaluating the Efficacy of Cognitive Enhancement. <i>Handbook of Experimental Pharmacology</i> , 2015, 228, 5-25.	1.8	3
87	Evaluation of cognitive function in bipolar disorder using the Brief Assessment of Cognition in Affective Disorders (BAC-A). <i>Journal of Psychiatric Research</i> , 2015, 60, 81-86.	3.1	28
88	Regressing to Prior Response Preference After Set Switching Implicates Striatal Dysfunction Across Psychotic Disorders: Findings From the B-SNIP Study. <i>Schizophrenia Bulletin</i> , 2015, 41, 940-950.	4.3	15
89	Validity and reliability of the Brazilian Portuguese version of the BACS (Brief Assessment of Cognition) Tj ETQq1 1 0,784314 rgBT /Overl 1.5 12	1.5	12
90	A Randomized, Placebo-Controlled Study Investigating the Nicotinic $\alpha 7$ Agonist, RG3487, for Cognitive Deficits in Schizophrenia. <i>Neuropsychopharmacology</i> , 2014, 39, 1568-1577.	5.4	71

#	ARTICLE	IF	CITATIONS
91	Neuropsychological Decline in Schizophrenia From the Premorbid to the Postonset Period: Evidence From a Population-Representative Longitudinal Study. <i>American Journal of Psychiatry</i> , 2014, 171, 91-101.	7.2	201
92	Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2014, 39, 1388-1398.	5.4	61
93	Validation of the Persian version of the Brief Assessment of Cognition in Schizophrenia in patients with schizophrenia and healthy controls. <i>Psychiatry and Clinical Neurosciences</i> , 2014, 68, 160-166.	1.8	17
94	Elevated Antisaccade Error Rate as an Intermediate Phenotype for Psychosis Across Diagnostic Categories. <i>Schizophrenia Bulletin</i> , 2014, 40, 1011-1021.	4.3	78
95	Cognition and Motivation as Treatment Targets in Schizophrenia. <i>JAMA Psychiatry</i> , 2014, 71, 987.	11.0	12
96	The Continuous Performance Test, Identical Pairs: norms, reliability and performance in healthy controls and patients with schizophrenia in Singapore. <i>Schizophrenia Research</i> , 2014, 156, 233-240.	2.0	10
97	The Brief Assessment of Cognition In Affective Disorders (BAC-A):Performance of patients with bipolar depression and healthy controls. <i>Journal of Affective Disorders</i> , 2014, 166, 86-92.	4.1	43
98	Altered Striatal Functional Connectivity in Subjects With an At-Risk Mental State for Psychosis. <i>Schizophrenia Bulletin</i> , 2014, 40, 904-913.	4.3	152
99	Behavioral response inhibition in psychotic disorders: Diagnostic specificity, familiarity and relation to generalized cognitive deficit. <i>Schizophrenia Research</i> , 2014, 159, 491-498.	2.0	58
100	Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia. <i>Psychopharmacology</i> , 2014, 231, 3647-3662.	3.1	54
101	Circadian rhythms in cognitive functioning among patients with schizophrenia: Impact on signal detection in clinical trials of potential pro-cognitive therapies. <i>Schizophrenia Research</i> , 2014, 159, 205-210.	2.0	11
102	Virtual reality functional capacity assessment in schizophrenia: Preliminary data regarding feasibility and correlations with cognitive and functional capacity performance. <i>Schizophrenia Research: Cognition</i> , 2014, 1, e21-e26.	1.3	44
103	Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis. <i>Psychiatry Research</i> , 2014, 218, 39-43.	3.3	13
104	Development of a Virtual Reality Assessment of Everyday Living Skills. <i>Journal of Visualized Experiments</i> , 2014, . .	0.3	18
105	P3-255: CULTURAL ADAPTATION OF TRANSLATED NEUROCOGNITIVE ASSESSMENTS IN RUSSIA, SWITZERLAND AND ITALY: PILOT TESTING FOR A PROGRAM TO DELAY THE ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE. , 2014, 10, P725-P726.		1
106	The Longitudinal Course of Cognitive Impairment in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 8-13.	2.2	110
107	Cognitive Effects of Pharmacotherapy for Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 864-876.	2.2	88
108	Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data. <i>Schizophrenia Bulletin</i> , 2013, 39, 564-574.	4.3	109

#	ARTICLE	IF	CITATIONS
109	Schizophrenia Is a Cognitive Illness. <i>JAMA Psychiatry</i> , 2013, 70, 1107.	11.0	649
110	Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. <i>Schizophrenia Research</i> , 2013, 150, 328-333.	2.0	46
111	Unraveling the relationship between obesity, schizophrenia and cognition. <i>Schizophrenia Research</i> , 2013, 151, 107-112.	2.0	32
112	Social cognition as a mediator between neurocognition and functional outcome in individuals at clinical high risk for psychosis. <i>Schizophrenia Research</i> , 2013, 150, 542-546.	2.0	47
113	Interview-based assessment of cognition in schizophrenia: Applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care. <i>Schizophrenia Research</i> , 2013, 146, 217-223.	2.0	14
114	The course of cognitive functioning over six months in individuals at clinical high risk for psychosis. <i>Psychiatry Research</i> , 2013, 206, 195-199.	3.3	25
115	The Longitudinal Youth at Risk Study (LYRIKS) – An Asian UHR perspective. <i>Schizophrenia Research</i> , 2013, 151, 279-283.	2.0	46
116	Formulation of the age×education index: Measuring age and education effects in neuropsychological performance. <i>Psychological Assessment</i> , 2013, 25, 61-70.	1.5	27
117	Preserved Working Memory and Altered Brain Activation in Persons at Risk for Psychosis. <i>American Journal of Psychiatry</i> , 2013, 170, 1297-1307.	7.2	27
118	Microvascular Abnormality in Schizophrenia as Shown by Retinal Imaging. <i>American Journal of Psychiatry</i> , 2013, 170, 1451-1459.	7.2	95
119	Neuropsychological Impairments in Schizophrenia and Psychotic Bipolar Disorder: Findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) Study. <i>American Journal of Psychiatry</i> , 2013, 170, 1275-1284.	7.2	320
120	Brief Assessment of Cognition in Schizophrenia: Normative Data in an English-Speaking Ethnic Chinese Sample. <i>Archives of Clinical Neuropsychology</i> , 2013, 28, 845-858.	0.5	14
121	The Cognitive Assessment Interview (CAI): Reliability and Validity of a Brief Interview-Based Measure of Cognition. <i>Schizophrenia Bulletin</i> , 2013, 39, 583-591.	4.3	50
122	Effects of Davunetide on N-acetylaspartate and Choline in Dorsolateral Prefrontal Cortex in Patients with Schizophrenia. <i>Neuropsychopharmacology</i> , 2013, 38, 1245-1252.	5.4	60
123	Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far?. <i>Schizophrenia Bulletin</i> , 2013, 39, 417-435.	4.3	117
124	How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS. <i>Cognitive Neuropsychiatry</i> , 2013, 18, 243-251.	1.3	9
125	Applicability of the MATRICS Consensus Cognitive Battery in Singapore. <i>Clinical Neuropsychologist</i> , 2013, 27, 455-469.	2.3	14
126	A Brain-Computer Interface Based Cognitive Training System for Healthy Elderly: A Randomized Control Pilot Study for Usability and Preliminary Efficacy. <i>PLoS ONE</i> , 2013, 8, e79419.	2.5	92

#	ARTICLE	IF	CITATIONS
127	Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials. <i>Innovations in Clinical Neuroscience</i> , 2013, 10, 4S-19S.	0.1	44
128	Clues to the Cognitive and Perceptual Origins of Social Isolation and Psychosis in Schizophrenia. <i>American Journal of Psychiatry</i> , 2012, 169, 354-357.	7.2	1
129	Standardizing the use of the Continuous Performance Test in schizophrenia research: A validation study. <i>Schizophrenia Research</i> , 2012, 142, 153-158.	2.0	21
130	Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. <i>Psychiatry Research</i> , 2012, 200, 835-842.	3.3	10
131	Persistent cannabis users show neuropsychological decline from childhood to midlife. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E2657-64.	7.1	1,173
132	Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. <i>Schizophrenia Research</i> , 2012, 136, 25-31.	2.0	110
133	A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. <i>Schizophrenia Research</i> , 2012, 138, 35-38.	2.0	30
134	Cognitive Impairment in Schizophrenia. <i>Handbook of Experimental Pharmacology</i> , 2012, , 11-37.	1.8	335
135	Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation. <i>Patient Preference and Adherence</i> , 2012, 6, 521.	1.8	7
136	Feasibility and Pilot Efficacy Results From the Multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) Randomized Controlled Trial. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1016-1022.	2.2	85
137	BL-1020, a New \hat{I}^3 -Aminobutyric Acid-Enhanced Antipsychotic. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e1168-e1174.	2.2	34
138	Technology, society, and mental illness: challenges and opportunities for assessment and treatment. <i>Innovations in Clinical Neuroscience</i> , 2012, 9, 47-50.	0.1	28
139	A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia. <i>Biological Psychiatry</i> , 2011, 69, 442-449.	1.3	155
140	Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. <i>Schizophrenia Research</i> , 2011, 125, 161-168.	2.0	183
141	The MCCB impairment profile for schizophrenia outpatients: Results from the MATRICS psychometric and standardization study. <i>Schizophrenia Research</i> , 2011, 126, 124-131.	2.0	204
142	Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. <i>Schizophrenia Research</i> , 2011, 127, 188-194.	2.0	86
143	Longitudinal consent-related abilities among research participants with schizophrenia: Results from the CATIE study. <i>Schizophrenia Research</i> , 2011, 130, 47-52.	2.0	28
144	Substance use and schizophrenia: Adverse correlates in the CATIE study sample. <i>Schizophrenia Research</i> , 2011, 132, 177-182.	2.0	56

#	ARTICLE	IF	CITATIONS
145	Comprehensive model of how reality distortion and symptoms occur in schizophrenia: Could impairment in learning-dependent predictive perception account for the manifestations of schizophrenia?. <i>Psychiatry and Clinical Neurosciences</i> , 2011, 65, 305-317.	1.8	18
146	Integrated genetic and genomic approach in the Singapore translational and clinical research in psychosis study: an overview. <i>Microbial Biotechnology</i> , 2011, 5, 91-99.	1.7	4
147	The Singapore flagship programme in translational and clinical research in psychosis. <i>Microbial Biotechnology</i> , 2011, 5, 290-300.	1.7	8
148	Criminal Justice System Involvement Among People with Schizophrenia. <i>Community Mental Health Journal</i> , 2011, 47, 727-736.	2.0	10
149	Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia. <i>Neuropsychopharmacology</i> , 2011, 36, 616-626.	5.4	103
150	Cognitive Effects of Atypical Antipsychotic Medications in Patients With Alzheimer's Disease: Outcomes From CATIE-AD. <i>American Journal of Psychiatry</i> , 2011, 168, 831-839.	7.2	232
151	The FDA-NIMH-MATRICES Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?. <i>Schizophrenia Bulletin</i> , 2011, 37, 1209-1217.	4.3	121
152	Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia.. <i>Psychological Assessment</i> , 2011, 23, 245-261.	1.5	45
153	Failures in Learning-Dependent Predictive Perception as the Key Cognitive Vulnerability to Psychosis in Schizophrenia. <i>Neuropsychopharmacology</i> , 2011, 36, 367-368.	5.4	14
154	A Brief Cognitive Assessment Tool for Schizophrenia: Construction of a Tool for Clinicians. <i>Schizophrenia Bulletin</i> , 2011, 37, 538-545.	4.3	77
155	Report From the Working Group Conference on Multisite Trial Design for Cognitive Remediation in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2011, 37, 1057-1065.	4.3	76
156	Methodological Issues in Negative Symptom Trials. <i>Schizophrenia Bulletin</i> , 2011, 37, 250-254.	4.3	67
157	Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 295-303.	2.2	57
158	No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 1115-1117.	1.7	9
159	Cortical and subcortical white matter abnormalities in adults with remitted first-episode mania revealed by Tract-Based Spatial Statistics. <i>Bipolar Disorders</i> , 2010, 12, 383-389.	1.9	48
160	Differential effects of emotional information on interference task performance across the life span. <i>Frontiers in Aging Neuroscience</i> , 2010, 2, .	3.4	18
161	Anticipating DSM-V: Opportunities and Challenges for Cognition and Psychosis. <i>Schizophrenia Bulletin</i> , 2010, 36, 43-47.	4.3	38
162	Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. <i>Current Medical Research and Opinion</i> , 2010, 26, 2403-2410.	1.9	44

#	ARTICLE	IF	CITATIONS
163	Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium_{title}Relationship to Family History and Conversion to Psychosis</sub><alt-title>Neuropsychology of Prodrome to Psychosis</alt-title>. Archives of General Psychiatry, 2010, 67, 578.	12.3	390
164	Circumstances Under Which Practice Does Not Make Perfect: A Review of the Practice Effect Literature in Schizophrenia and Its Relevance to Clinical Treatment Studies. Neuropsychopharmacology, 2010, 35, 1053-1062.	5.4	109
165	Static and Dynamic Cognitive Deficits in Childhood Preceding Adult Schizophrenia: A 30-Year Study. American Journal of Psychiatry, 2010, 167, 160-169.	7.2	483
166	The Cognitive Assessment Interview (CAI): Development and validation of an empirically derived, brief interview-based measure of cognition. Schizophrenia Research, 2010, 121, 24-31.	2.0	76
167	The Schizophrenia Cognition Rating Scale: Validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia. Psychiatry Research, 2010, 178, 33-38.	3.3	17
168	Armodafinil as Adjunctive Therapy in Adults With Cognitive Deficits Associated With Schizophrenia. Journal of Clinical Psychiatry, 2010, 71, 1475-1481.	2.2	43
169	A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia. PLoS Genetics, 2009, 5, e1000373.	3.5	383
170	Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia. Neuropsychopharmacology, 2009, 34, 1885-1903.	5.4	168
171	White matter abnormalities and neurocognitive deficits associated with the passivity phenomenon in schizophrenia: A diffusion tensor imaging study. Psychiatry Research - Neuroimaging, 2009, 172, 121-127.	1.8	28
172	Memory-Prediction Errors and Their Consequences in Schizophrenia. Neuropsychology Review, 2009, 19, 336-352.	4.9	29
173	Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. BMC Psychiatry, 2009, 9, 44.	2.6	57
174	Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. European Journal of Human Genetics, 2009, 17, 946-957.	2.8	89
175	Abbreviated neuropsychological assessment in schizophrenia: Prediction of different aspects of outcome. Journal of Clinical and Experimental Neuropsychology, 2009, 31, 462-471.	1.3	60
176	Schizophrenia is a disorder of higher order hierarchical processing. Medical Hypotheses, 2009, 72, 740-744.	1.5	19
177	Development and psychometric performance of the schizophrenia objective functioning instrument: An interviewer administered measure of function. Schizophrenia Research, 2009, 107, 275-285.	2.0	40
178	Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research, 2009, 107, 1-12.	2.0	129
179	Commentary on O'Halloran et al. Schizophrenia Research, 2009, 107, 327-329.	2.0	2
180	The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research, 2009, 115, 17-23.	2.0	85

#	ARTICLE	IF	CITATIONS
181	Measuring memory-prediction errors and their consequences in youth at risk for schizophrenia. <i>Annals of the Academy of Medicine, Singapore</i> , 2009, 38, 414-6.	0.4	9
182	Employment Outcomes in a Randomized Trial of Second-Generation Antipsychotics and Perphenazine in the Treatment of Individuals with Schizophrenia. <i>Journal of Behavioral Health Services and Research</i> , 2008, 35, 215-225.	1.4	19
183	The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 1298-1300.	1.7	25
184	Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study. <i>Schizophrenia Research</i> , 2008, 105, 1-9.	2.0	79
185	Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). <i>Schizophrenia Research</i> , 2008, 102, 108-115.	2.0	281
186	Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Neuropsychopharmacology</i> , 2008, 33, 1217-1228.	5.4	135
187	Science and Recovery in Schizophrenia. <i>Psychiatric Services</i> , 2008, 59, 487-496.	2.0	133
188	The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity. <i>American Journal of Psychiatry</i> , 2008, 165, 203-213.	7.2	1,863
189	Functional Co-Primary Measures for Clinical Trials in Schizophrenia: Results From the MATRICS Psychometric and Standardization Study. <i>American Journal of Psychiatry</i> , 2008, 165, 221-228.	7.2	204
190	Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia. <i>American Journal of Psychiatry</i> , 2008, 165, 978-987.	7.2	182
191	The MATRICS Consensus Cognitive Battery, Part 2: Co-Norming and Standardization. <i>American Journal of Psychiatry</i> , 2008, 165, 214-220.	7.2	593
192	Should cognitive impairment be included in the diagnostic criteria for schizophrenia?. <i>World Psychiatry</i> , 2008, 7, 22-28.	10.4	132
193	Extrapyramidal side-effects of antipsychotics in a randomised trial. <i>British Journal of Psychiatry</i> , 2008, 193, 279-288.	2.8	228
194	Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. <i>Journal of the International Neuropsychological Society</i> , 2008, 14, 209-21.	1.8	41
195	Special Section on Implications of CATIE: What CATIE Found: Results From the Schizophrenia Trial. <i>Psychiatric Services</i> , 2008, 59, 500-506.	2.0	110
196	Cognition and schizophrenia: is there a role for cognitive assessments in diagnosis and treatment?. <i>Psychiatry</i> , 2008, 5, 55-9.	0.3	2
197	Dr. Keefe and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2007, 164, 1911-1912.	7.2	1
198	Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 103-111.	1.4	24

#	ARTICLE	IF	CITATIONS
199	Effects of Olanzapine, Quetiapine, and Risperidone on Neurocognitive Function in Early Psychosis: A Randomized, Double-Blind 52-Week Comparison. <i>American Journal of Psychiatry</i> , 2007, 164, 1061-1071.	7.2	234
200	Implementation Considerations for Multisite Clinical Trials with Cognitive Neuroscience Tasks. <i>Schizophrenia Bulletin</i> , 2007, 34, 656-663.	4.3	21
201	Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. <i>Archives of General Psychiatry</i> , 2007, 64, 633.	12.3	928
202	How Should DSM-V Criteria for Schizophrenia Include Cognitive Impairment?. <i>Schizophrenia Bulletin</i> , 2007, 33, 912-920.	4.3	332
203	Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study. <i>American Journal of Psychiatry</i> , 2007, 164, 428-436.	7.2	246
204	Cognition as an outcome measure in schizophrenia. <i>British Journal of Psychiatry</i> , 2007, 191, s46-s51.	2.8	72
205	Lamotrigine as Add-On Therapy in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 582-589.	1.4	112
206	Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATIE Study. <i>American Journal of Psychiatry</i> , 2007, 164, 415-427.	7.2	138
207	Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients. <i>European Psychiatry</i> , 2007, 22, 365-370.	0.2	31
208	AKT1 and Neurocognition in Schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2007, 41, 169-177.	2.3	12
209	NCAM1 and Neurocognition in Schizophrenia. <i>Biological Psychiatry</i> , 2007, 61, 902-910.	1.3	80
210	Risperidone and Cognitive Function in Children With Disruptive Behavior Disorders. <i>Biological Psychiatry</i> , 2007, 62, 226-234.	1.3	26
211	Sensitivity and applicability of the Brazilian version of the Brief Assessment of Cognition in Schizophrenia (BACS). <i>Dementia E Neuropsychologia</i> , 2007, 1, 260-265.	0.8	14
212	Brief Assessment of Cognition in Schizophrenia: Validation of the Japanese version. <i>Psychiatry and Clinical Neurosciences</i> , 2007, 61, 602-609.	1.8	206
213	Cognitive deficits in patients with schizophrenia: effects and treatment. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 14, 8-13.	2.2	26
214	Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis. <i>Biological Psychiatry</i> , 2006, 59, 97-105.	1.3	113
215	One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. <i>Schizophrenia Research</i> , 2006, 81, 1-15.	2.0	114
216	Optimization of a multinomial model for investigating hallucinations and delusions with source monitoring. <i>Schizophrenia Research</i> , 2006, 85, 106-112.	2.0	23

#	ARTICLE	IF	CITATIONS
217	A longitudinal study of neurocognitive function in individuals at-risk for psychosis. <i>Schizophrenia Research</i> , 2006, 88, 26-35.	2.0	236
218	Insight in first-episode psychosis. <i>Psychological Medicine</i> , 2006, 36, 1385-1393.	4.5	115
219	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>American Journal of Psychiatry</i> , 2006, 163, 611-622.	7.2	312
220	Dr. Lieberman and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2006, 163, 555-a-556.	7.2	2
221	Special Section on CATIE Baseline Data: Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial. <i>Psychiatric Services</i> , 2006, 57, 1094-1101.	2.0	112
222	Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 2080-2089.	7.2	247
223	Barriers to Employment for People With Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 411-417.	7.2	390
224	The Relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to Functional Capacity and Real-world Functional Outcome. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2006, 28, 260-269.	1.3	129
225	Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial. <i>Neuropsychopharmacology</i> , 2006, 31, 2033-2046.	5.4	408
226	The Schizophrenia Cognition Rating Scale: An Interview-Based Assessment and Its Relationship to Cognition, Real-World Functioning, and Functional Capacity. <i>American Journal of Psychiatry</i> , 2006, 163, 426-432.	7.2	325
227	Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. <i>American Journal of Psychiatry</i> , 2006, 163, 600-610.	7.2	760
228	Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. <i>American Journal of Psychiatry</i> , 2006, 163, 600.	7.2	513
229	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>American Journal of Psychiatry</i> , 2006, 163, 611.	7.2	221
230	Missing the sweet spot disengagement in schizophrenia. <i>Psychiatry</i> , 2006, 3, 36-41.	0.3	0
231	Measuring outcome priorities and preferences in people with schizophrenia. <i>British Journal of Psychiatry</i> , 2005, 187, 529-536.	2.8	74
232	Antipsychotic Drug Effects on Brain Morphology in First-Episode Psychosis. <i>Archives of General Psychiatry</i> , 2005, 62, 361.	12.3	712
233	Altered Prefrontal Dopaminergic Function in Chronic Recreational Ketamine Users. <i>American Journal of Psychiatry</i> , 2005, 162, 2352-2359.	7.2	149
234	Research with Spanish-Speaking Populations in the United States: Lost in the Translation A Commentary and a Plea. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2005, 27, 555-564.	1.3	28

#	ARTICLE	IF	CITATIONS
235	Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. <i>New England Journal of Medicine</i> , 2005, 353, 1209-1223.	27.0	5,335
236	Defining a cognitive function decrement in schizophrenia. <i>Biological Psychiatry</i> , 2005, 57, 688-691.	1.3	312
237	The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. <i>Schizophrenia Research</i> , 2005, 80, 9-18.	2.0	189
238	Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2005, 80, 33-43.	2.0	146
239	Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2005, 80, 1-8.	2.0	80
240	Comparative Effect of Atypical and Conventional Antipsychotic Drugs on Neurocognition in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Low Doses of Haloperidol. <i>American Journal of Psychiatry</i> , 2004, 161, 985-995.	7.2	289
241	Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICES conference to select cognitive domains and test criteria. <i>Biological Psychiatry</i> , 2004, 56, 301-307.	1.3	818
242	The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. <i>Schizophrenia Research</i> , 2004, 68, 283-297.	2.0	1,209
243	Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 361-72.	2.2	59
244	Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications. <i>Psychopharmacology</i> , 2003, 169, 383-389.	3.1	25
245	Neurocognitive Assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project Schizophrenia Trial: Development, Methodology, and Rationale. <i>Schizophrenia Bulletin</i> , 2003, 29, 45-55.	4.3	111
246	Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources. <i>Schizophrenia Research</i> , 2002, 57, 51-67.	2.0	155
247	Sensory acuity and reasoning in delusional disorder. <i>Comprehensive Psychiatry</i> , 2002, 43, 175-178.	3.1	24
248	Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment. <i>American Journal of Psychiatry</i> , 2001, 158, 176-184.	7.2	581
249	Visuospatial working memory in schizotypal personality disorder patients. <i>Schizophrenia Research</i> , 2000, 41, 447-455.	2.0	75
250	Test-Retest Reliability of the Dot Test of Visuospatial Working Memory in Patients with Schizophrenia and Controls. <i>Schizophrenia Research</i> , 2000, 45, 169-173.	2.0	15
251	The Effects of Atypical Antipsychotic Drugs on Neurocognitive Impairment in Schizophrenia: A Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 1999, 25, 201-222.	4.3	636
252	Do Novel Antipsychotics Improve Cognition? A Report of a Meta-Analysis. <i>Psychiatric Annals</i> , 1999, 29, 623-629.	0.1	6

#	ARTICLE	IF	CITATIONS
253	Cognitive Impairment in Schizophrenia and Implications of Atypical Neuroleptic Treatment. <i>CNS Spectrums</i> , 1997, 2, 41-55.	1.2	40
254	Eye Tracking, Attention, and Schizotypal Symptoms in Nonpsychotic Relatives of Patients With Schizophrenia. <i>Archives of General Psychiatry</i> , 1997, 54, 169.	12.3	109
255	Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay. <i>Schizophrenia Research</i> , 1997, 26, 9-14.	2.0	70
256	Attentional and eye tracking deficits correlate with negative symptoms in schizophrenia. <i>Schizophrenia Research</i> , 1997, 26, 139-146.	2.0	33
257	Lifetime comorbidity, lifetime history of psychosis and suicide attempts, and current symptoms of patients with deteriorated affective disorder. <i>Psychiatry Research</i> , 1997, 73, 33-45.	3.3	4
258	D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder. <i>Schizophrenia Research</i> , 1996, 20, 29-32.	2.0	51
259	Information-processing markers of vulnerability to schizophrenia: performance of patients with schizotypal and nonschizotypal personality disorders. <i>Psychiatry Research</i> , 1996, 60, 49-56.	3.3	45
260	Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: Effects of typical neuroleptics on the brief psychiatric rating scale. <i>Biological Psychiatry</i> , 1996, 40, 755-760.	1.3	36
261	Impact of neuroleptic medications on continuous performance test measures in schizophrenia. <i>Biological Psychiatry</i> , 1996, 39, 902-905.	1.3	29
262	Schizophrenia: All Pathways to Symptoms Pass Through Cognitive Deficits?. <i>PsycCritiques</i> , 1996, 41, 900-902.	0.0	0
263	Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. <i>Psychiatry Research</i> , 1995, 59, 127-136.	3.3	125
264	A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. <i>Schizophrenia Research</i> , 1995, 17, 25-33.	2.0	165
265	Cognitive impairment as a target for pharmacological treatment in schizophrenia. <i>Schizophrenia Research</i> , 1995, 17, 123-129.	2.0	60
266	Progress in Experimental Personality and Psychopathology Research, vol. 15. <i>American Journal of Psychiatry</i> , 1995, 152, 288-289.	7.2	24
267	Performance of nonpsychotic relatives of schizophrenic patients on cognitive tests. <i>Psychiatry Research</i> , 1994, 53, 1-12.	3.3	133
268	Empirical assessment of the factorial structure of clinical symptoms in schizophrenic patients: Formal thought disorder. <i>Psychiatry Research</i> , 1992, 44, 141-151.	3.3	62
269	Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: Negative symptoms. <i>Psychiatry Research</i> , 1992, 44, 153-165.	3.3	99
270	Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms. <i>Schizophrenia Research</i> , 1991, 4, 71-79.	2.0	43

#	ARTICLE	IF	CITATIONS
271	Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. <i>Psychiatry Research</i> , 1991, 38, 285-292.	3.3	32
272	Attentional markers of vulnerability to schizophrenia: Performance of medicated and unmedicated patients and normals. <i>Psychiatry Research</i> , 1990, 33, 179-188.	3.3	57
273	Eye tracking, schizophrenic symptoms, and schizotypal personality disorder. <i>European Archives of Psychiatry and Neurological Sciences</i> , 1989, 239, 39-42.	0.9	24
274	symptom correlates of poor eye tracking in patients with schizotypal personality disorder and relatives of schizophrenic probands. <i>Biological Psychiatry</i> , 1989, 25, A102-A103.	1.3	1
275	Biologic markers for personality disorders: A dimensional approach. <i>Biological Psychiatry</i> , 1989, 25, A140.	1.3	0
276	Using family history screening for linkage studies in schizophrenia. <i>Biological Psychiatry</i> , 1989, 25, A144.	1.3	0
277	Neurocognition. , 0, , 97-119.		2
278	The importance of treating cognition in schizophrenia and other severe mental illnesses: background, strategies, and findings to date. , 0, , 177-191.		0
279	Assessment of cognition in schizophrenia treatment studies. , 0, , 231-246.		0